Long-term Topical Cyclosporine for Atopic Keratoconjunctivitis

Key facts

Sponsor

Johns Hopkins University

Principal Investigator

Esen K Akpek, MD

Johns Hopkins Hospital - Wilmer Eye Institute

Intervention

Cyclosporin 0.05% ophthalmic(drug)

Enrollment

12 enrolled

Eligibility

18 years · All sexes

Timeline

2007 – 2009

Study locations (1)

• Johns Hopkins Hospital - Wilmer Eye Institute, Baltimore, Maryland, United States

Primary source

Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.

Other trials for Atopic keratoconjunctivitis

Additional recruiting or active studies for the same condition.

• RECRUITINGPHASE3NCT07395232
  An Efficacy and Safety Study of DFL24498 in the Treatment of AKC
  Dompé Farmaceutici S.p.A
• ACTIVE NOT RECRUITINGNCT04973384
  Ocular Comorbidity in Atopic Dermatitis
  Rigshospitalet, Denmark

See all trials for Atopic keratoconjunctivitis →